Moderna, Inc.

Moderna, Inc. is a biotechnology company that develops and commercializes messenger RNA (mRNA) medicines for a wide range of diseases. Its respiratory vaccine portfolio includes Spikevax for COVID-19, mNEXSPIKE, mRESVIA for RSV, and vaccines for seasonal influenza, combination, and pandemic influenza. The company also works on latent vaccines targeting cytomegalovirus, Epstein-Barr virus, and HIV; enteric vaccines like norovirus; public health vaccines for Zika, Nipah, and Mpox; bacterial disease vaccines such as Lyme; oncology therapeutics including intismeran autogene, cancer antigen therapy, T-cell engager, and cell therapy enhancer; and rare disease products for propionic acidemia, methylmalonic acidemia, and cystic fibrosis. Moderna collaborates with partners like Merck, Vertex Pharmaceuticals, and the Bill & Melinda Gates Foundation.

Moderna, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol MRNA. Its shares are traded in United States Dollars (USD). As a US-based company, it is part of the US region and its stock is accessible to investors through major US brokerages. The exchange listing provides liquidity and transparency for shareholders, with the company being a prominent player in the biotechnology sector.

Moderna operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology firm, it focuses on leveraging mRNA technology to develop innovative medicines and vaccines. This industry is characterized by high research and development costs, regulatory hurdles, and the potential for breakthrough therapies. Moderna's work spans infectious diseases, oncology, and rare genetic disorders, placing it at the forefront of mRNA-based therapeutics.

Moderna is headquartered in Cambridge, Massachusetts, United States. It was founded in 2010 and originally named Moderna Therapeutics, Inc. before rebranding in August 2018. The company provides its messenger RNA medicines globally, serving markets around the world. Its international reach is supported by strategic alliances with organizations such as the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Advanced Research Projects Agency (DARPA), as well as collaborations with global health foundations.

Moderna's notable products include Spikevax, its COVID-19 vaccine, and mRESVIA for respiratory syncytial virus (RSV). The company also has a pipeline of vaccines for seasonal influenza, combination vaccines, and pandemic influenza. In oncology, it develops intismeran autogene and other therapies. Moderna has strategic alliances with Merck & Co., Vertex Pharmaceuticals, and immatics N.V., among others. It also partners with government agencies like BARDA and DARPA, and non-profits such as the Bill & Melinda Gates Foundation and the Institute for Life Changing Medicines. These collaborations help advance its mRNA platform across multiple therapeutic areas.